Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

TEToby EyreLMLeyla MohseninejadLBLianne Barnieh

Discussion

Loading...

Member takes

Overview

Indirect comparison demonstrates better progression-free survival with zanubrutinib over ibrutinib in relapsed mantle cell lymphoma, indicating improved outcomes.

Key Points

  • This study aims to compare the efficacy of zanubrutinib and ibrutinib for treating relapsed/refractory mantle cell lymphoma (MCL).
  • Conducted a matching-adjusted indirect comparison (MAIC) using data from clinical trials of zanubrutinib and ibrutinib.
  • Identified and pooled data from two single-arm trials for zanubrutinib and multiple studies for ibrutinib.
  • Match covariates included age, gender, performance status, and previous treatment history.
  • Zanubrutinib showed significantly better progression-free survival (PFS) than ibrutinib (HR 0.54 before matching, HR 0.63 after matching).
  • Overall survival (OS) was also significantly better with zanubrutinib compared to ibrutinib (HR 0.42 before matching, HR 0.46 after matching).
  • Results remained consistent across various sensitivity analyses.

Cite This Study

Eyre et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db27https://doi.org/10.1182/blood-2025-5365
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma2026
  2. 2Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma2025
  3. 3Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up2026
  4. 4Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).2024 · 3 citations
  5. 5Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma2025 · 1 citations